Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Epidemiology Forecast - 2034
Description
Key Highlights
Among the two types of Prostate cancer (mCSPC and mCRPC), mCRPC was more prevalent in 2024 in the 7MM.
The number of people in Japan diagnosed with prostate cancer has sharply increased, rising by 1.8 times over the last 10 years. Although more people are being diagnosed with cancer due to the aging of the population, among other reasons, prostate cancer in particular is surging at a rapid pace.
Prostate cancer is most frequently diagnosed among men aged 65–74 years; the median age at diagnosis is 66 years.
As per the secondary analysis, roughly 60% of patients present with localized or locally advanced cases (Stage I–III), 30% experience biochemical recurrence or progression, and the remaining are metastatic cases.
Due to the inherent limitations of PSA, there is a growing need for additional diagnostic and prognostic tools to enhance early detection and enable more accurate risk stratification.
The emergence of PSMA-PET imaging have significantly improved the diagnostic landscape of advanced prostate cancer.
DelveInsight’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of TRH, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Understanding
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. It is common in men of 50–64 years and over age 65; however, it can occur in men younger than 50 years. Symptoms of adenocarcinoma of the prostate include blood in the semen, frequent urge to urinate, and painful urination and ejaculation. The symptoms of prostate cancer do not usually appear until the prostate is large enough to affect the tube that carries urine from the bladder out of the penis.
Metastatic Castration-Resistant Prostate Cancer Diagnosis
Diagnosing prostate cancer involves various methods, including analyzing PSA levels in the blood, conducting a digital rectal exam to feel for abnormalities, performing a biopsy to examine tissue samples, utilizing genetic testing to identify potential risk factors, conducting imaging tests like ultrasound or MRI to visualize the prostate, and occasionally conducting a bone scan to check for metastasis. These tests are typically used together to comprehensively assess prostate health and detect any signs of cancer.
Further details related to country-based variations are provided in the report…
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidemiology
The epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent cases of Prostate cancer, Five–year Prevalent cases of Prostate cancer, Age-specific cases of Prostate cancer, Total cases of Prostate cancer by clinical stages, Total Prevalent cases of mCRPC in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
In 2024, the 7MM had approximately 7 million prevalent cases of prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2025-2034).
The five-year prevalent cases of prostate cancer in the US was approximately 1,100,000 in 2024.
Among the EU4 and the UK, Germany accounted for the highest number of metastatic CRPC cases while, Spain had the lowest cases, in 2024.
As per the analysis, in the United States, approximately 40% of prostate cancer cases are diagnosed in individuals aged 65-74 years, representing the most common age group for this disease.
The total cases of mCRPC in the US comprised approximately 52,000 in 2024 and are projected to increase during the forecast period.
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Report Insights
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidem Report Insights
Patient population
Country-wise epidemiology distribution
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Report Key Strengths
Ten years forecast
7MM coverage
mCRPC epidemiology segmentation
FAQs
What are the disease risks, burdens, and unmet needs of mCRPC? What will be the growth opportunities across the 7MM concerning the patient population with mCRPC?
What is the historical and forecasted TRH patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
How are prevalent mCRPC cases distributed across different age groups?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
A detailed overview of age-specific cases of mCRPC is included.
Among the two types of Prostate cancer (mCSPC and mCRPC), mCRPC was more prevalent in 2024 in the 7MM.
The number of people in Japan diagnosed with prostate cancer has sharply increased, rising by 1.8 times over the last 10 years. Although more people are being diagnosed with cancer due to the aging of the population, among other reasons, prostate cancer in particular is surging at a rapid pace.
Prostate cancer is most frequently diagnosed among men aged 65–74 years; the median age at diagnosis is 66 years.
As per the secondary analysis, roughly 60% of patients present with localized or locally advanced cases (Stage I–III), 30% experience biochemical recurrence or progression, and the remaining are metastatic cases.
Due to the inherent limitations of PSA, there is a growing need for additional diagnostic and prognostic tools to enhance early detection and enable more accurate risk stratification.
The emergence of PSMA-PET imaging have significantly improved the diagnostic landscape of advanced prostate cancer.
DelveInsight’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of TRH, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Understanding
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. It is common in men of 50–64 years and over age 65; however, it can occur in men younger than 50 years. Symptoms of adenocarcinoma of the prostate include blood in the semen, frequent urge to urinate, and painful urination and ejaculation. The symptoms of prostate cancer do not usually appear until the prostate is large enough to affect the tube that carries urine from the bladder out of the penis.
Metastatic Castration-Resistant Prostate Cancer Diagnosis
Diagnosing prostate cancer involves various methods, including analyzing PSA levels in the blood, conducting a digital rectal exam to feel for abnormalities, performing a biopsy to examine tissue samples, utilizing genetic testing to identify potential risk factors, conducting imaging tests like ultrasound or MRI to visualize the prostate, and occasionally conducting a bone scan to check for metastasis. These tests are typically used together to comprehensively assess prostate health and detect any signs of cancer.
Further details related to country-based variations are provided in the report…
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidemiology
The epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent cases of Prostate cancer, Five–year Prevalent cases of Prostate cancer, Age-specific cases of Prostate cancer, Total cases of Prostate cancer by clinical stages, Total Prevalent cases of mCRPC in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
In 2024, the 7MM had approximately 7 million prevalent cases of prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2025-2034).
The five-year prevalent cases of prostate cancer in the US was approximately 1,100,000 in 2024.
Among the EU4 and the UK, Germany accounted for the highest number of metastatic CRPC cases while, Spain had the lowest cases, in 2024.
As per the analysis, in the United States, approximately 40% of prostate cancer cases are diagnosed in individuals aged 65-74 years, representing the most common age group for this disease.
The total cases of mCRPC in the US comprised approximately 52,000 in 2024 and are projected to increase during the forecast period.
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Report Insights
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidem Report Insights
Patient population
Country-wise epidemiology distribution
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Report Key Strengths
Ten years forecast
7MM coverage
mCRPC epidemiology segmentation
FAQs
What are the disease risks, burdens, and unmet needs of mCRPC? What will be the growth opportunities across the 7MM concerning the patient population with mCRPC?
What is the historical and forecasted TRH patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
How are prevalent mCRPC cases distributed across different age groups?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
A detailed overview of age-specific cases of mCRPC is included.
Table of Contents
217 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary of mCRPC
- 4. Epidemiology Methodology
- 5. mCRPC Epidemiology Overview at a Glance
- 5.1. Patient Share (%) Distribution of mCRPC in 2020 in the 7MM
- 5.2. Patient Share (%) Distribution of mCRPC in 2034 in the 7MM
- 6. Disease Background and Overview
- 6.1. Signs and Symptoms of Prostate Cancer
- 6.2. Risk Factors and Causes of Prostate Cancer
- 6.3. Stages of Prostate Cancer
- 6.4. Pathophysiology of Prostate Cancer
- 6.5. Diagnosis of Prostate Cancer
- 6.5.1. Tests to Diagnose Prostate Cancer
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Prevalent Cases of Prostate Cancer in the 7MM
- 7.4. Five-year Prevalent Cases of Prostate Cancer in the 7MM
- 7.5. Total Prevalent Cases of mCRPC in the 7MM
- 7.6. The United States
- 7.6.1. Five-year Prevalent Cases of Prostate Cancer in the US
- 7.6.2. Age-specific Cases of Prostate Cancer in the US
- 7.6.3. Total Cases of Prostate Cancer by Clinical Stages in the US
- 7.6.4. Total Prevalent Cases of mCRPC in the US
- 7.7. EU4 and the UK
- 7.7.1. Five-year Prevalent Cases of Prostate Cancer in EU4 and the UK
- 7.7.2. Age-specific Cases of Prostate Cancer in the EU4 and the UK
- 7.7.3. Total Cases of Prostate Cancer by Clinical Stages in the EU4 and the UK
- 7.7.4. Total Prevalent Cases of mCRPC in EU4 and the UK
- 7.8. Japan
- 7.8.1. Five-year Prevalent Cases of Prostate Cancer in Japan
- 7.8.2. Age-specific Cases of Prostate Cancer in Japan
- 7.8.3. Total Cases of Prostate Cancer by Clinical Stages in Japan
- 7.8.4. Total Prevalent Cases of mCRPC in Japan
- 8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
